We aim to provide real-world evidence on the use of ocrelizumab for treating multiple sclerosis (MS), with specific regard to prescription pattern, adherence, persistence, healthcare resource utilization and related costs, also in relation to other disease-modifying treatments (DMTs).
Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy / Moccia, Marcello; Affinito, Giuseppina; Berera, Giulia; Marrazzo, Giuseppina; Piscitelli, Raffaele; Carotenuto, Antonio; Petracca, Maria; Lanzillo, Roberta; Triassi, Maria; Brescia Morra, Vincenzo; Palladino, Raffaele. - In: JOURNAL OF NEUROLOGY. - ISSN 1432-1459. - 269:12(2022), pp. 6504-6511. [10.1007/s00415-022-11320-7]
Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy
Moccia, Marcello;Affinito, Giuseppina;Carotenuto, Antonio;Petracca, Maria;Lanzillo, Roberta;Triassi, Maria;Brescia Morra, Vincenzo;Palladino, Raffaele
2022
Abstract
We aim to provide real-world evidence on the use of ocrelizumab for treating multiple sclerosis (MS), with specific regard to prescription pattern, adherence, persistence, healthcare resource utilization and related costs, also in relation to other disease-modifying treatments (DMTs).I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
